~~<i id='3E0206BBBF'><strike id='3E0206BBBF'><tt id='3E0206BBBF'><pre id='3E0206BBBF'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

leisure time

author：entertainment 2025-09-29 10:40:22 - browse：66163

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： BD to buy Edwards patient monitoring unit for $4.2 billion

hotspot

knowledge

explore

leisure time

IanWaldie/GettyImagesBectonDickinsonplanstopay$4.2billionforEdwardsLifesciences’criticalcarebusiness

WSS

Dexcom's push to bring CGM to type 2 diabetes patients

Undocumented workers face uncertainty as immigration law takes effect in Florida

FDA approves Moderna’s RSV vaccine, its second licensed product

Sutter Health’s antitrust win overturned by appeals court

ASCO Takeaways: Winners, snoozers, and the art of cancer care

For pregnant people, addiction treatment shouldn't mean a call to child protective services

knowledge

leisure time

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT wants to know your pick for a great summer read or listen

Heart attack and stroke risk calculators need revising

Dexcom's push to bring CGM to type 2 diabetes patients

Novavax promises a turnaround & Lilly roils the obesity market

Lupron, used to halt puberty in children, may cause lasting health problems

Wildfire smoke exposes gaps in outdoor worker protections

Beware reading your test results before your doctor does

Duchenne breakthrough therapy leaves behind pioneering families

Senators tussle over abortion against the backdrop of a presidential campaign

hotspot

Elevance PBM president out as customers face prescription chaos

Illumina board agrees to spin off Grail, as divestment plans proceed

STAT wants to know your pick for a great summer read or listen

A new initiative will help leaders fight the next pandemic

An outdated Medicare rule harms dementia patients with anxiety

Take antibiotics after sex, CDC recommends for certain risk groups

knowledge

explore

leisure time

leisure time